GENASYS INC

Genasys insiders shift capital: CFO forgoes 11,667 RSUs, CEO sells 200,000 shares—yet a new health‑tech partnership may boost earnings and future valuation.

Insider buying by Genasys’ board signals confidence in its new public‑safety roadmap, but investors must watch for earnings growth amid recent stock decline.

Genasys CEO Danforth Richard’s 400,000‑share restricted‑share purchase signals strong insider confidence, tied to 2026 performance metrics—watch the Feb 10 earnings for validation.